| API | Indication | Micronised | CEP | EU DMF | US DMF | JP DMF | KR DMF | CN DMF |
|---|---|---|---|---|---|---|---|---|
| Abediterol | Asthma and COPD | |||||||
| Aclidinium bromide | COPD | |||||||
| Batefenterol | COPD | |||||||
| Benserazide | Parkinson's disease | |||||||
| Imidafenacin p | Urinary incontinence | |||||||
| Olodaterol p | COPD | |||||||
| Paliperidone palmitate | Schizophrenia, bipolar mania | |||||||
| Pipamparone | Schizophrenia | |||||||
| Revefenacin | COPD | |||||||
| Rivaroxaban | Thrombosis. Stroke | • | ||||||
| Tafamidis | Transthyretin amyloisosis | |||||||
| Tolvaptan | Hponatremia | |||||||
| Umeclidinium bromide | COPD | |||||||
| Vilanterol | Asthma and COPD |
P = Patent applications/granted patents owned by Neuraxpharm
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / INKE. All rights reserved.